HUE054495T2 - Rák kezelésére szolgáló készítmény - Google Patents

Rák kezelésére szolgáló készítmény

Info

Publication number
HUE054495T2
HUE054495T2 HUE12160586A HUE12160586A HUE054495T2 HU E054495 T2 HUE054495 T2 HU E054495T2 HU E12160586 A HUE12160586 A HU E12160586A HU E12160586 A HUE12160586 A HU E12160586A HU E054495 T2 HUE054495 T2 HU E054495T2
Authority
HU
Hungary
Prior art keywords
cancer
preparation
treatment
Prior art date
Application number
HUE12160586A
Other languages
English (en)
Hungarian (hu)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE054495(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of HUE054495T2 publication Critical patent/HUE054495T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE12160586A 2006-08-25 2007-08-23 Rák kezelésére szolgáló készítmény HUE054495T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25

Publications (1)

Publication Number Publication Date
HUE054495T2 true HUE054495T2 (hu) 2021-09-28

Family

ID=38916904

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12160586A HUE054495T2 (hu) 2006-08-25 2007-08-23 Rák kezelésére szolgáló készítmény

Country Status (20)

Country Link
EP (3) EP2061561B1 (enExample)
JP (10) JP2010501575A (enExample)
KR (4) KR20200125776A (enExample)
CN (2) CN101528308A (enExample)
AU (6) AU2007287098C1 (enExample)
CA (1) CA2661422C (enExample)
CY (2) CY1115477T1 (enExample)
DK (2) DK2061561T3 (enExample)
ES (2) ES2869343T3 (enExample)
HR (2) HRP20130961T1 (enExample)
HU (1) HUE054495T2 (enExample)
IL (3) IL197211A0 (enExample)
LT (1) LT2478907T (enExample)
NO (2) NO20091190L (enExample)
NZ (1) NZ597830A (enExample)
PL (2) PL2478907T3 (enExample)
PT (2) PT2478907T (enExample)
RS (2) RS62034B1 (enExample)
SI (2) SI2478907T1 (enExample)
WO (1) WO2008024484A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200125776A (ko) * 2006-08-25 2020-11-04 코우가 바이오테크놀로지, 인크. 암을 치료하기 위한 방법 및 조성물
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
WO2009057795A2 (en) * 2007-10-29 2009-05-07 Takeda Pharmaceutical Company Limited Pyrrolo [1,2-c] imidazole derivatives for use im the prophylaxis or treatment of cancer which is refractory to known cancer therapies
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
MX356704B (es) 2011-01-11 2018-06-11 Novartis Ag Combinación.
JP6239497B2 (ja) 2011-04-01 2017-11-29 ジェネンテック， インコーポレイテッド Ａｋｔ阻害剤化合物及びアビラテロンの組み合わせ、及び使用方法
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
CA2872541A1 (en) * 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
MX2015013247A (es) * 2013-03-15 2016-11-25 Iceutica Inc Formulacion de acetato de abiraterona.
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
MX2015014046A (es) * 2013-04-04 2016-05-16 Exelixis Inc Combinaciones de farmacos para tratar cancer.
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
EP4265300B1 (en) * 2013-10-01 2025-12-10 Novartis AG Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
BR112016006970A2 (pt) * 2013-10-01 2017-08-01 Novartis Ag enzalutamida em combinação com afuresertib para o tratamento de câncer
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
EP3280448B1 (en) * 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
SI3490560T1 (sl) 2016-07-29 2025-04-30 Janssen Pharmaceutica, N.V. Niraparib za uporabo pri metodi zdravljenja raka prostate
JOP20190244A1 (ar) * 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
BR112020007439A2 (pt) 2017-10-16 2020-10-27 Aragon Pharmaceuticals, Inc. antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastática
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
KR102879575B1 (ko) * 2019-03-06 2025-11-03 프로펠라 쎄라퓨틱스, 인크. 아비라테론 프로드러그
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
IL297338A (en) * 2020-04-16 2022-12-01 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO2001064251A2 (en) * 2000-03-02 2001-09-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
AU2002219472A1 (en) * 2001-01-02 2002-07-16 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
DE60318092T2 (de) * 2002-10-23 2008-11-27 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
US20050054620A1 (en) * 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
KR20200125776A (ko) * 2006-08-25 2020-11-04 코우가 바이오테크놀로지, 인크. 암을 치료하기 위한 방법 및 조성물

Also Published As

Publication number Publication date
EP2478907B1 (en) 2021-04-14
CA2661422A1 (en) 2008-02-28
NZ597830A (en) 2013-02-22
JP2018065859A (ja) 2018-04-26
JP2020114851A (ja) 2020-07-30
IL197211A0 (en) 2009-12-24
PL2478907T3 (pl) 2021-10-25
PL2061561T3 (pl) 2013-12-31
JP2021038252A (ja) 2021-03-11
NO20200775A1 (no) 2009-03-20
DK2061561T3 (da) 2013-10-07
EP3804730A1 (en) 2021-04-14
IL227746A0 (en) 2013-09-30
SI2478907T1 (sl) 2021-08-31
AU2007287098C1 (en) 2018-03-15
JP6053279B2 (ja) 2016-12-27
JP2012082215A (ja) 2012-04-26
JP2019059750A (ja) 2019-04-18
JP2010501575A (ja) 2010-01-21
HRP20130961T1 (hr) 2013-11-22
CY1115477T1 (el) 2017-01-04
KR20150108946A (ko) 2015-09-30
KR20090059126A (ko) 2009-06-10
NO20091190L (no) 2009-03-20
JP2015110577A (ja) 2015-06-18
CY1124221T1 (el) 2022-05-27
CN101528308A (zh) 2009-09-09
RS62034B1 (sr) 2021-07-30
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
LT2478907T (lt) 2021-06-25
HK1131577A1 (en) 2010-01-29
AU2015221447A1 (en) 2015-09-17
RS52956B (sr) 2014-02-28
JP2017052791A (ja) 2017-03-16
AU2015221447B2 (en) 2016-12-15
WO2008024484A1 (en) 2008-02-28
PT2478907T (pt) 2021-05-26
ES2869343T3 (es) 2021-10-25
DK2478907T3 (da) 2021-05-25
PT2061561E (pt) 2013-10-09
HRP20210670T1 (hr) 2021-06-11
AU2015221447B9 (en) 2017-07-20
JP6740497B2 (ja) 2020-08-12
EP2478907A3 (en) 2012-08-01
JP2022185091A (ja) 2022-12-13
CA2661422C (en) 2017-06-27
AU2018271331A1 (en) 2018-12-20
EP2061561A1 (en) 2009-05-27
CN104306977A (zh) 2015-01-28
AU2017201764A1 (en) 2017-04-06
ES2428634T3 (es) 2013-11-08
AU2007287098B2 (en) 2013-08-15
EP2478907A2 (en) 2012-07-25
SI2061561T1 (sl) 2013-11-29
JP2024164147A (ja) 2024-11-26
KR20180003636A (ko) 2018-01-09
IL257681A (en) 2018-04-30
AU2007287098A1 (en) 2008-02-28
AU2022206696A1 (en) 2022-08-11
JP6445123B2 (ja) 2018-12-26
KR20200125776A (ko) 2020-11-04

Similar Documents

Publication Publication Date Title
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
IL248204A0 (en) Combined treatment of tumors expressing 38cd
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK2121139T3 (da) Formulations for cancer treatment
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
IL243376A0 (en) Antagonist antibody against epha2 for the treatment of cancer
BRPI0821779A2 (pt) tratamento terapêutico de câncer
IL197315A0 (en) Treatment of cancer
BRPI0810206A2 (pt) Método de tratar câncer
PT2115472E (pt) Biomarcadores de cancro
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
DK2035369T3 (da) Terapeutiske
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
DK2173831T3 (da) Brøndbehandling
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
DK2147122T3 (da) Enzymatisk kræftbehandling
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
HUE038563T2 (hu) Rák kezelési eljárás
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten